Summary
Thermo Fisher Scientific Inc. (TMO) filed its 2012 10-K on February 27, 2013, detailing its financial performance and strategic positioning. The company continued to demonstrate strong execution, driven by its diverse portfolio of products and services that serve a broad range of customers in life sciences research, healthcare, industrial, and applied markets. Key to its success was the ongoing integration of its acquired businesses and a focus on innovation to maintain its competitive edge. Investors should note the company's commitment to expanding its global reach and investing in high-growth areas within the life sciences sector.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $12.51B |
| Cost of Revenue | $6.10B |
| Gross Profit | $6.41B |
| R&D Expenses | $376.40M |
| SG&A Expenses | $3.35B |
| Operating Expenses | $11.03B |
| Operating Income | $1.48B |
| Interest Expense | $241.60M |
| Net Income | $1.18B |
| EPS (Basic) | $3.24 |
| EPS (Diluted) | $3.21 |
| Shares Outstanding (Basic) | 363.80M |
| Shares Outstanding (Diluted) | 366.60M |
Key Highlights
- 1Thermo Fisher Scientific operates in a dynamic and growing life sciences and diagnostics market.
- 2The company's diversified business model across various end markets (life sciences research, healthcare, industrial, applied) provides resilience.
- 3Strategic acquisitions and integrations are a key part of the company's growth strategy.
- 4Focus on innovation and product development to drive organic growth.
- 5Commitment to expanding global presence and serving a broad customer base.
- 6The company is well-positioned to benefit from trends in personalized medicine and biopharmaceutical manufacturing.
Frequently Asked Questions
Thermo Fisher Scientific generates revenue from a wide array of products and services, including analytical instruments, laboratory equipment, reagents, consumables, software, and services for scientific research, diagnostics, and industrial applications. Key segments often include Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
The company employs a multi-pronged strategy for growth, encompassing organic growth through innovation and new product development, as well as inorganic growth through strategic acquisitions. It focuses on integrating acquired businesses effectively to realize synergies and expand its market reach.
Key trends include the increasing demand for biopharmaceuticals and biologics manufacturing, advancements in genetic sequencing and gene editing, the growth of personalized medicine, and the need for advanced diagnostic tools. The company's investments are often aligned with these significant market shifts.
SEC filings, such as the 10-K annual report, provide crucial audited financial information, management discussions, risk factors, and disclosures about the company's operations, strategy, and governance. They are essential for investors to make informed decisions about the company's performance and prospects.